Kuros Biosciences completed enrollment in a Level 1 clinical study, comparing MagnetOs Bone Graft Granules to the gold standard of autograft bone in patients undergoing posterolateral lumbar fusion.
Data from the prospective, multi-center, intra-patient controlled trial showed a fusion rate for MagnetOs of 78%, compared to 42% for autograft. This compares favorably to fusion rates of 55% to 71% reported for other synthetic bone grafts evaluated in similar, well-controlled studies of posterolateral fusion.
The first consecutive 50 patients (from a total of 100) requiring up to four-level instrumented posterolateral lumbar fusion were included in this preliminary analysis. The rate of posterolateral lumbar/thoracolumbar fusion was assessed by CT-scan at 12 months post-op.
Joost de Bruijn, Chief Executive Officer of Kuros, said, “We are pleased to complete enrolment in the trial and take another step forward in the clinical phase of Project Fusion with MagnetOs, with the aim of delivering the ideal bone graft. Previous bone grafts have been sold on the premise of improved clinical outcomes but based on benchtop or preclinical data, so we are excited to demonstrate MagnetOs’ effect in a high-level clinical setting.”
Kuros Biosciences completed enrollment in a Level 1 clinical study, comparing MagnetOs Bone Graft Granules to the gold standard of autograft bone in patients undergoing posterolateral lumbar fusion.
Data from the prospective, multi-center, intra-patient controlled trial showed a fusion rate for MagnetOs of 78%, compared to 42% for autograft....
Kuros Biosciences completed enrollment in a Level 1 clinical study, comparing MagnetOs Bone Graft Granules to the gold standard of autograft bone in patients undergoing posterolateral lumbar fusion.
Data from the prospective, multi-center, intra-patient controlled trial showed a fusion rate for MagnetOs of 78%, compared to 42% for autograft. This compares favorably to fusion rates of 55% to 71% reported for other synthetic bone grafts evaluated in similar, well-controlled studies of posterolateral fusion.
The first consecutive 50 patients (from a total of 100) requiring up to four-level instrumented posterolateral lumbar fusion were included in this preliminary analysis. The rate of posterolateral lumbar/thoracolumbar fusion was assessed by CT-scan at 12 months post-op.
Joost de Bruijn, Chief Executive Officer of Kuros, said, “We are pleased to complete enrolment in the trial and take another step forward in the clinical phase of Project Fusion with MagnetOs, with the aim of delivering the ideal bone graft. Previous bone grafts have been sold on the premise of improved clinical outcomes but based on benchtop or preclinical data, so we are excited to demonstrate MagnetOs’ effect in a high-level clinical setting.”
Copy to clipboard 
